Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BROADWAY obicetrapib phase 3 trial in inadequately controlled dyslipidemia with HeFH and/or ASCVD
2021-005065-40Phase 3Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- Mar 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dyslipidemia, hypercholesterolemia, familial hypercholesterolemia (FH) and 1 more comparing Obicetrapib 10 mg plus background lipid-modifying therapy with Placebo plus background lipid-modifying therapy (2 arms). Started Mar 2022; status: completed.
02
Drugs
obicetrapib
03
Conditions
dyslipidemiahypercholesterolemiafamilial hypercholesterolemia (FH)atherosclerotic disease
Beyond the preview
Go deeper on 2021-005065-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005065-40.